New Fred Hutch spinoff to commercialize cord blood stem cell therapies based on work by Drs. Colleen Delaney, Irwin Bernstein
Dec. 3, 2015
| By Susan Keown / Fred Hutch News Service
A new Fred Hutch spinoff, Nohla Therapeutics, will commercialize cord blood stem cell therapies based on work by Dr. Colleen Delaney and Dr. Irwin Bernstein. In preliminary studies, the company’s first product helps stem cells engraft more quickly after transplant and protects patients from deadly infections during this vulnerable period.
Ex-patient’s wife recalls how her sacred mission to save her husband led her to Fred Hutch
Aug. 26, 2015
| By Bill Briggs / Fred Hutch News Service
After her husband, Hugh, was diagnosed with an aggressive form of leukemia, Aimee Fagan filled a notebook with doctors' names, study results, and this mantra: 'It's you and me against cancer, do you think it has a chance?'
Stem cell donor, recipient meet each other – and researchers who made transplant possible
April 29, 2015
| By Linda Dahlstrom / Fred Hutch News Service
Leukemia survivor Mark Tose had one burning question for Dr. Mary Flowers: How much of the connection he feels with the donor for the transplant that saved his life is because they were biologically a perfect match — or is something else at play? "It feels like we've known each other forever," he said.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.